Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of all lung cancer cases.[1] Crizotinib, the first small molecule inhibitor of anaplastic lymphoma kinase (ALK), was approved in the United States in 2011 for the treatment of patients with ALK-positive NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.